Cantor Fitzgerald Downgrades Spectrum Pharmaceuticals to Neutral, Lowers Price Target to $4

Cantor Fitzgerald analyst Alethia Young downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Overweight to Neutral and lowers the price target from $17 to $4.

Benzinga · 12/26/2019 14:30

Cantor Fitzgerald analyst Alethia Young downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Overweight to Neutral and lowers the price target from $17 to $4.